GAO Finds Hemophilia Rx Reimbursement Follows Familiar AWP Pattern
Executive Summary
Hemophilia treatment centers purchase blood clotting factor from manufacturers at prices 35% to 48% below AWP, a General Accounting Office report states
You may also be interested in...
Senate AWP Plan Directs HHS To Determine “Market Price” For Chemotherapy
The Senate Finance Committee's Medicare reform bill includes a provision directing HHS to determine actual "market prices" for reimbursement of outpatient drugs currently covered under part B
Senate AWP Plan Directs HHS To Determine “Market Price” For Chemotherapy
The Senate Finance Committee's Medicare reform bill includes a provision directing HHS to determine actual "market prices" for reimbursement of outpatient drugs currently covered under part B
Medicare “Inherent Reasonableness” Standard Should Be Clarified, BIO Says
The Centers for Medicare & Medicaid Services should clarify its guidelines for applying the "inherent reasonableness" standard to coverage decisions, the Biotechnology Industry Organization says